08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Clino, Astellas deal

Clino granted Astellas worldwide rights to develop and commercialize adeno-associated virus (AAV)-modified Volvox channelrhodopsin-1 (ChR1) to treat retinitis pigmentosa. The product is an engineered photoreceptive ion channel. The partners declined to disclose additional details. Clino...